Azathioprine is not a biologic. It is a conventional, chemically synthesized drug classified as an immunosuppressive antimetabolite. This is a common point of confusion because azathioprine suppresses the immune system, and so do biologics, but the two belong to fundamentally different categories of medicine.
Why Azathioprine Is Not a Biologic
The distinction comes down to how a drug is made and what it’s made of. Biologics are large, complex molecules derived from living organisms, such as engineered antibodies grown in cell cultures. They’re too large and fragile to survive the digestive system, which is why they need to be injected or infused. Azathioprine, by contrast, is a small molecule manufactured through chemical synthesis in a lab. Its chemical structure is well-defined: it’s an imidazolyl derivative of 6-mercaptopurine, a purine analogue. You take it as a daily pill.
That oral tablet is itself a practical clue. If you can swallow it and it works, it’s almost certainly a small-molecule drug rather than a biologic. Biologics would be broken down in your stomach before they could reach their target.
How Azathioprine Actually Works
Once you swallow azathioprine, your body converts it into its active form, 6-mercaptopurine, which then gets broken down further into several metabolites. These metabolites interfere with your immune system in two key ways. First, they mimic the building blocks of DNA (purines) and get incorporated into replicating DNA, disrupting the process. Second, they block one of the pathways your cells use to manufacture new purines in the first place. The net effect is that rapidly dividing immune cells can’t replicate as efficiently, which dials down the immune response.
One of its metabolites also interferes with a specific signaling protein inside immune cells, blocking a co-stimulatory signal that T cells need to become fully activated. This is a more targeted effect than the general DNA disruption, and it was only discovered well after the drug entered clinical use in the 1960s.
How Biologics Differ
Biologics used in the same conditions as azathioprine work in a completely different way. Rather than broadly slowing immune cell replication, they typically block one specific molecule in the inflammatory cascade. For example, some biologics are engineered antibodies that bind to tumor necrosis factor (TNF), a key inflammatory signaling protein, neutralizing it before it can trigger inflammation. Others target different immune signals like interleukins or integrins.
Because biologics are so much larger and more complex, they’re also far more expensive to produce. In a cost-effectiveness analysis of Crohn’s disease treatments published by Monash University, initial treatment with azathioprine cost roughly $35,000 over the study period, while combination therapy with the biologic infliximab cost approximately $57,600. The annual out-of-pocket difference can be dramatic depending on insurance coverage, and this cost gap is one reason azathioprine remains widely used despite being an older drug.
Where Azathioprine Fits in Treatment
Azathioprine is FDA-approved for preventing organ rejection after kidney transplants and for treating rheumatoid arthritis. It’s also widely prescribed off-label for inflammatory bowel disease, lupus, and other autoimmune conditions. In clinical guidelines, it’s grouped with drugs called “immunomodulators” or “conventional immunosuppressants,” a category that sits between basic anti-inflammatory drugs (like corticosteroids) and biologics in terms of treatment intensity.
Current American Gastroenterological Association guidelines for moderate-to-severe Crohn’s disease recommend against using azathioprine alone to get active disease under control. However, they do recommend it for maintaining remission once corticosteroids have brought a flare under control. The guidelines also suggest combining azathioprine with the biologic infliximab rather than using infliximab alone, particularly in patients who haven’t taken azathioprine before. In this combination role, azathioprine helps reduce the body’s tendency to develop antibodies against the biologic, which can make the biologic less effective over time.
Genetic Testing Before Starting
One practical difference between azathioprine and most biologics is that your doctor may order a genetic test before prescribing it. Azathioprine is broken down by an enzyme called TPMT, and about 10% of people carry gene variants that make this enzyme less active. If you’re one of them, a standard dose can cause a dangerous buildup of active metabolites, leading to severe drops in white blood cell counts and increased infection risk.
People with intermediate TPMT activity typically start on a reduced dose, which has been shown to lower the rate of toxicity without sacrificing effectiveness. People with very low or absent TPMT activity are generally switched to a different medication altogether. A second enzyme, NUDT15, also plays a role in breaking down the drug’s active metabolites, and variants in that gene are particularly common in people of East Asian descent. Testing for both enzymes before starting treatment is now recommended in major pharmacogenetic guidelines.
The Bottom Line on Drug Class
Azathioprine is a synthetic, small-molecule immunosuppressant. It belongs in the same broad category as methotrexate and mycophenolate, not in the category of biologics like infliximab, adalimumab, or ustekinumab. The two types of drugs often treat the same conditions and are sometimes used together, but they differ in their molecular structure, how they’re manufactured, how they’re taken, how they work inside the body, and what they cost.